National Institute of Diabetes and Digestive and Kidney Diseases; Amended Notice of Meeting, 27155 [E9-13289]
Download as PDF
Federal Register / Vol. 74, No. 108 / Monday, June 8, 2009 / Notices
Bethesda, MD 20892–7616. 301–451–2606.
tshahan@niaid.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: June 1, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E9–13285 Filed 6–5–09; 8:45 am]
BILLING CODE 4140–01–P
Dated: June 1, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E9–13287 Filed 6–5–09; 8:45 am]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meetings
cprice-sewell on PRODPC61 with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; Review of a Th17
Autoimmunity Program Project Application.
Date: June 23, 2009.
Time: 1 p.m. to 4 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6700B
Rockledge Drive, Bethesda, MD 20817
(Telephone Conference Call).
Contact Person: Quirijn Vos, PhD,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
NIH/NIAID/DHHS, 6700B Rockledge Drive,
MSC 7616, Bethesda, MD 20892, 301–451–
2666, qvos@niaid.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: Microbiology,
Infectious Diseases and AIDS Initial Review
Group; Microbiology and Infectious Diseases
Research Committee.
Date: June 25, 2009.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Residence Inn Bethesda, 7335
Wisconsin Avenue, Bethesda, MD 20814.
VerDate Nov<24>2008
15:15 Jun 05, 2009
Jkt 217001
Contact Person: Annie Walker-Abbey, PhD,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
NIH/NIAID/DHHS, 6700B Rockledge Drive,
Rm. 3126, Bethesda, MD 20892–7616, 301–
451–2671, aabbey@niaid.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and
Digestive and Kidney Diseases;
Amended Notice of Meeting
Notice is hereby given of a change in
the meeting of the National Institute of
Diabetes and Digestive and Kidney
Diseases Special Emphasis Panel, July
13, 2009, 8 a.m. to July 13, 2009, 5 p.m.,
Washingtonian Center Courtyard, 204
Boardwalk Place, Gaithersburg, MD
20878 which was published in the
Federal Register on May 27, 2009, 74
FR 12248.
The meeting has been changed to July
14, 2009, from 8 a.m. to 4 p.m. The
location remains the same. The meeting
is closed to the public.
Dated: June 1, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E9–13289 Filed 6–5–09; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2009–N–0664]
Cardiovascular and Renal Drugs
Advisory Committee; Notice of Meeting
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
This notice announces a forthcoming
meeting of a public advisory committee
of the Food and Drug Administration
PO 00000
Frm 00068
Fmt 4703
Sfmt 4703
27155
(FDA). The meeting will be open to the
public.
Name of Committee: Cardiovascular
and Renal Drugs Advisory Committee.
General Function of the Committee:
To provide advice and
recommendations to the agency on
FDA’s regulatory issues.
Date and Time: The meeting will be
held on July 28, 2009, from 8 a.m. to 5
p.m.
Location: Hilton Washington DC/
Silver Spring, Maryland Ballroom, 8727
Colesville Rd, Silver Spring, MD. The
hotel telephone number is 301–589–
5200.
Contact Person: Elaine Ferguson,
Center for Drug Evaluation and Research
(HFD–21), Food and Drug
Administration, 5600 Fishers Lane (for
express delivery, 5630 Fishers Lane, rm.
1093), Rockville, MD 20857, 301–827–
7001, FAX: 301–827–6776, e-mail:
elaine.ferguson@fda.hhs.gov, or FDA
Advisory Committee Information Line,
1–800–741–8138 (301–443–0572 in the
Washington, DC area), code
3014512533. Please call the Information
Line for up-to-date information on this
meeting. A notice in the Federal
Register about last minute modifications
that impact a previously announced
advisory committee meeting cannot
always be published quickly enough to
provide timely notice. Therefore, you
should always check the agency’s Web
site and call the appropriate advisory
committee hot line/phone line to learn
about possible modifications before
coming to the meeting.
Agenda: The committee will discuss
new drug application (NDA) 22–449,
binodenoson injectable, lypholized
solid 250 micrograms vial, King
Pharmaceuticals Research and
Development, Inc., for the proposed
indication: Short acting coronary
vasodilator for use as an adjunct to
noninvasive myocardial perfusion
imaging tests to detect perfusion
abnormalities in patients with known or
suspected coronary artery disease.
FDA intends to make background
material available to the public no later
than 2 business days before the meeting.
If FDA is unable to post the background
material on its Web site prior to the
meeting, the background material will
be made publicly available at the
location of the advisory committee
meeting, and the background material
will be posted on FDA’s Web site after
the meeting. Background material is
available at https://www.fda.gov/
AdvisoryCommittees/Calendar/
default.htm, click on the year 2009 and
scroll down to the appropriate advisory
committee link.
E:\FR\FM\08JNN1.SGM
08JNN1
Agencies
[Federal Register Volume 74, Number 108 (Monday, June 8, 2009)]
[Notices]
[Page 27155]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-13289]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and Digestive and Kidney Diseases;
Amended Notice of Meeting
Notice is hereby given of a change in the meeting of the National
Institute of Diabetes and Digestive and Kidney Diseases Special
Emphasis Panel, July 13, 2009, 8 a.m. to July 13, 2009, 5 p.m.,
Washingtonian Center Courtyard, 204 Boardwalk Place, Gaithersburg, MD
20878 which was published in the Federal Register on May 27, 2009, 74
FR 12248.
The meeting has been changed to July 14, 2009, from 8 a.m. to 4
p.m. The location remains the same. The meeting is closed to the
public.
Dated: June 1, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. E9-13289 Filed 6-5-09; 8:45 am]
BILLING CODE 4140-01-P